Cargando…
Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women
INTRODUCTION: To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women. MATERIAL AND METHODS: Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planne...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297632/ https://www.ncbi.nlm.nih.gov/pubmed/34321985 http://dx.doi.org/10.5114/pm.2021.106089 |
_version_ | 1783725896891367424 |
---|---|
author | Cetin, Esra Can Guven, Suleyman Sal, Hidayet Guvendag Guven, Emine Seda Mentese, Ahmet |
author_facet | Cetin, Esra Can Guven, Suleyman Sal, Hidayet Guvendag Guven, Emine Seda Mentese, Ahmet |
author_sort | Cetin, Esra Can |
collection | PubMed |
description | INTRODUCTION: To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women. MATERIAL AND METHODS: Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planned to have HT for menopausal symptoms were enrolled in this prospective study. The serum İMA levels were recorded before and after (3 months, 6 months, 12 months later) hormone treatment (2 mg estradiol hemihydrate). RESULTS: The mean age of women was 47.60 ± 2.34 years. The mean serum IMA levels were 0.610 ± 0.096 absorbance units (ABSU) at the beginning and 0.484 ± 0.080 ABSU after 3 months of hormone therapy. Following 6 months of hormone therapy, serum IMA level was 0.546 ± 0.075, and reached 0.580 ± 0.089 ABSU following 12 months of therapy. CONCLUSIONS: These findings suggest that HT may not block the menopause induced ischemia process. Although HT had a positive effect on serum IMA levels following 3 months’ use, serum IMA levels returned to baseline levels after 12 months’ use. Based on this study’s findings, long-term use of HT may not have a positive effect on cardiovascular disease protection. |
format | Online Article Text |
id | pubmed-8297632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-82976322021-07-27 Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women Cetin, Esra Can Guven, Suleyman Sal, Hidayet Guvendag Guven, Emine Seda Mentese, Ahmet Prz Menopauzalny Original Paper INTRODUCTION: To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women. MATERIAL AND METHODS: Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planned to have HT for menopausal symptoms were enrolled in this prospective study. The serum İMA levels were recorded before and after (3 months, 6 months, 12 months later) hormone treatment (2 mg estradiol hemihydrate). RESULTS: The mean age of women was 47.60 ± 2.34 years. The mean serum IMA levels were 0.610 ± 0.096 absorbance units (ABSU) at the beginning and 0.484 ± 0.080 ABSU after 3 months of hormone therapy. Following 6 months of hormone therapy, serum IMA level was 0.546 ± 0.075, and reached 0.580 ± 0.089 ABSU following 12 months of therapy. CONCLUSIONS: These findings suggest that HT may not block the menopause induced ischemia process. Although HT had a positive effect on serum IMA levels following 3 months’ use, serum IMA levels returned to baseline levels after 12 months’ use. Based on this study’s findings, long-term use of HT may not have a positive effect on cardiovascular disease protection. Termedia Publishing House 2021-05-23 2021-06 /pmc/articles/PMC8297632/ /pubmed/34321985 http://dx.doi.org/10.5114/pm.2021.106089 Text en Copyright: © 2021 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Cetin, Esra Can Guven, Suleyman Sal, Hidayet Guvendag Guven, Emine Seda Mentese, Ahmet Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women |
title | Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women |
title_full | Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women |
title_fullStr | Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women |
title_full_unstemmed | Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women |
title_short | Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women |
title_sort | serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297632/ https://www.ncbi.nlm.nih.gov/pubmed/34321985 http://dx.doi.org/10.5114/pm.2021.106089 |
work_keys_str_mv | AT cetinesracan serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen AT guvensuleyman serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen AT salhidayet serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen AT guvendagguvenemineseda serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen AT menteseahmet serumischemiamodifiedalbuminlevelreturnstoitspremenopausallevelwith1yearhormonetherapyinhealthymenopausalwomen |